AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Pfizer (PFE) posted a 1.16% revenue decline due to COVID product collapses (Paxlovid down 70%, Comirnaty down 33%) and took a $4.4B non-cash impairment charge. AbbVie has already completed its post-Humira transition with two approved, scaling drugs expanding into new indications, while Pfizer is betting billions on future obesity acquisitions including the $7B Metsera deal with no near-term commercial payoff, leaving Pfizer dependent on 20 pivotal trial starts in 2026 to justify its pipeline valuation. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE AbbVie NYSE:ABBV ) and Pfizer NYSE:PFE ) both reported fourth quarter earnings in early February. AbbVie posted record net sales with revenue up 10% year over year, powered by a post-Humira immunology rebuild that is now clearly working. Pfizer posted a slight revenue decline of 1.16% while absorbing a massive COVID hangover and betting billions on obesity drugs it does not yet own commerc
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer (PFE) is now covered by CICC Research. They set an "outperform" rating on the stock.MarketBeat
- UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target [Yahoo! Finance]Yahoo! Finance
- Pfizer (PFE) had its price target raised by UBS Group AG from $25.00 to $27.00. They now have a "neutral" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target raised by Morgan Stanley from $27.00 to $28.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a "neutral" rating on the stock.MarketBeat
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 4/17/26 - Form 4
- 4/16/26 - Form 4
- 4/10/26 - Form 3
- PFE's page on the SEC website